121 related articles for article (PubMed ID: 9733598)
1. Irsogladine maleate inhibits angiogenesis in wild-type and plasminogen activator-deficient mice.
Ren CJ; Ueda F; Roses DF; Harris MN; Mignatti P; Rifkin DB; Shapiro RL
J Surg Res; 1998 Jul; 77(2):126-31. PubMed ID: 9733598
[TBL] [Abstract][Full Text] [Related]
2. The role of the fibrinolytic system in corneal angiogenesis.
Vogten JM; Reijerkerk A; Meijers JC; Voest EE; Borel Rinkes IH; Gebbink MF
Angiogenesis; 2003; 6(4):311-6. PubMed ID: 15166500
[TBL] [Abstract][Full Text] [Related]
3. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
4. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1.
Gutierrez LS; Schulman A; Brito-Robinson T; Noria F; Ploplis VA; Castellino FJ
Cancer Res; 2000 Oct; 60(20):5839-47. PubMed ID: 11059781
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in P- and E-selectin-deficient mice.
Hartwell DW; Butterfield CE; Frenette PS; Kenyon BM; Hynes RO; Folkman J; Wagner DD
Microcirculation; 1998; 5(2-3):173-8. PubMed ID: 9789257
[TBL] [Abstract][Full Text] [Related]
6. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
7. The novel tubulin-binding drug BTO-956 inhibits R3230AC mammary carcinoma growth and angiogenesis in Fischer 344 rats.
Shan S; Lockhart AC; Saito WY; Knapp AM; Laderoute KR; Dewhirst MW
Clin Cancer Res; 2001 Aug; 7(8):2590-6. PubMed ID: 11489843
[TBL] [Abstract][Full Text] [Related]
8. A role of fibrinolytic activity in angiogenesis. Quantitative assay using in vitro method.
Yasunaga C; Nakashima Y; Sueishi K
Lab Invest; 1989 Dec; 61(6):698-704. PubMed ID: 2481153
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of action of angiostatic steroids: suppression of plasminogen activator activity via stimulation of plasminogen activator inhibitor synthesis.
Blei F; Wilson EL; Mignatti P; Rifkin DB
J Cell Physiol; 1993 Jun; 155(3):568-78. PubMed ID: 7684043
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activities of a novel indolin-2-ketone compound, Z24: more potent inhibition on bFGF-induced angiogenesis and bcl-2 over-expressing cancer cells.
Wang LL; Li JJ; Zheng ZB; Liu HY; Du GJ; Li S
Eur J Pharmacol; 2004 Oct; 502(1-2):1-10. PubMed ID: 15464084
[TBL] [Abstract][Full Text] [Related]
11. Flavonoids inhibit VEGF/bFGF-induced angiogenesis in vitro by inhibiting the matrix-degrading proteases.
Kim MH
J Cell Biochem; 2003 Jun; 89(3):529-38. PubMed ID: 12761886
[TBL] [Abstract][Full Text] [Related]
12. Wound healing angiogenesis: indirect stimulation by basic fibroblast growth factor.
Knighton DR; Phillips GD; Fiegel VD
J Trauma; 1990 Dec; 30(12 Suppl):S134-44. PubMed ID: 1701493
[TBL] [Abstract][Full Text] [Related]
13. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth.
Rogers MS; Christensen KA; Birsner AE; Short SM; Wigelsworth DJ; Collier RJ; D'Amato RJ
Cancer Res; 2007 Oct; 67(20):9980-5. PubMed ID: 17942931
[TBL] [Abstract][Full Text] [Related]
14. [Roles of serine proteases and matrix metalloproteinases in tumor invasion and angiogenesis].
Masson V
Bull Mem Acad R Med Belg; 2006; 161(5):320-6. PubMed ID: 17283905
[TBL] [Abstract][Full Text] [Related]
15. A model of angiogenesis in the mouse cornea.
Kenyon BM; Voest EE; Chen CC; Flynn E; Folkman J; D'Amato RJ
Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1625-32. PubMed ID: 8675406
[TBL] [Abstract][Full Text] [Related]
16. The mouse cornea micropocket angiogenesis assay.
Rogers MS; Birsner AE; D'Amato RJ
Nat Protoc; 2007; 2(10):2545-50. PubMed ID: 17947997
[TBL] [Abstract][Full Text] [Related]
17. Involvement of molecules related to angiogenesis, proteolysis and apoptosis in implantation in rhesus monkey and mouse.
Liu YX; Gao F; Wei P; Chen XL; Gao HJ; Zou RJ; Siao LJ; Xu FH; Feng Q; Liu K; Hu ZY
Contraception; 2005 Apr; 71(4):249-62. PubMed ID: 15792644
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen mediates liver regeneration and angiogenesis after experimental partial hepatectomy.
Drixler TA; Vogten JM; Gebbink MF; Carmeliet P; Voest EE; Borel Rinkes IH
Br J Surg; 2003 Nov; 90(11):1384-90. PubMed ID: 14598419
[TBL] [Abstract][Full Text] [Related]
19. Tissue type plasminogen activator facilitates NMDA-receptor-mediated retinal apoptosis through an independent fibrinolytic cascade.
Kumada M; Niwa M; Hara A; Matsuno H; Mori H; Ueshima S; Matsuo O; Yamamoto T; Kozawa O
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1504-7. PubMed ID: 15790922
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
